A genomic analysis of primary AML patient samples from the BEAT AML database revealed that KRAS or PTPN11 mutations were associated with higher VEN area under the curve (AUC) values, indicating increased resistance to the drug [38]. This evidence concerns the gene PTPN11 and acute myeloid leukemia.